Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission

Kensuke Usuki; Saiko Kurosawa; Naoyuki Uchida; Kazuaki Yakushiji; Fusako Waki; Eijo Matsuishi; Kumiko Kagawa; Tatsuo Furukawa; Yoshinobu Maeda; Manabu Shimoyama; Hiroatsu Ago; Yujiro Yamano; Shingo Yano; Naohito Fujishima; Yasushi Takamatsu; Tetsuya Eto; Michihiro Hidaka; Hitoshi Matsuoka; Takahiro Fukuda

doi:10.1016/j.clml.2012.07.004

Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission

Kensuke Usuki, Saiko Kurosawa, Naoyuki Uchida, Kazuaki Yakushiji, Fusako Waki, Eijo Matsuishi, Kumiko Kagawa, Tatsuo Furukawa, Yoshinobu Maeda, Manabu Shimoyama, Hiroatsu Ago, Yujiro Yamano, Shingo Yano, Naohito Fujishima, Yasushi Takamatsu, Tetsuya Eto, Michihiro Hidaka, Hitoshi Matsuoka, Takahiro Fukuda

Graduate School of Medicine Dentistry and Pharmaceutical Sciences

Research output: Contribution to journal › Article

9 Citations (Scopus)

Abstract

Introduction: A number of randomized trials in patients with AML in CR1 have been conducted and they showed that auto-HCT improves RFS but not OS, compared with chemotherapy. However, because these trials have had compliance problems, the value of auto-HCT still has not been clearly established. Patients and Methods: Using a database of 2518 adult patients with AML in CR1, we retrospectively analyzed the outcome of auto-HCT and compared it with intensive nonmyeloablative chemotherapy using landmark analyses. Results: In 103 auto-HCT recipients, OS and RFS at 3 years from treatment were 65% and 57%, respectively. Multivariate analysis showed that unfavorable risk cytogenetics and entry into CR1 after 2 courses of induction treatment predicted a poor outcome. Because the median time interval between CR1 and auto-HCT was 153 days, landmark analyses at 5 months after CR1 were performed to compare 1290 patients who received chemotherapy alone (median age, 52 years; range, 16-70) with 103 who received auto-HCT (median age, 48 years; range, 16-67). Auto-HCT improves 3-year RFS (58% vs. 37%; P

Original language	English
Pages (from-to)	444-451
Number of pages	8
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	12
Issue number	6
DOIs	https://doi.org/10.1016/j.clml.2012.07.004
Publication status	Published - Dec 2012

Fingerprint

Keywords

AML
Autologous transplantation
CR1
inv(16)
Postremission therapy
t(8;21)

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Cite this

Usuki, K., Kurosawa, S., Uchida, N., Yakushiji, K., Waki, F., Matsuishi, E., Kagawa, K., Furukawa, T., Maeda, Y., Shimoyama, M., Ago, H., Yamano, Y., Yano, S., Fujishima, N., Takamatsu, Y., Eto, T., Hidaka, M., Matsuoka, H., & Fukuda, T. (2012). Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission. Clinical Lymphoma, Myeloma and Leukemia, 12(6), 444-451. https://doi.org/10.1016/j.clml.2012.07.004

Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission. / Usuki, Kensuke; Kurosawa, Saiko; Uchida, Naoyuki; Yakushiji, Kazuaki; Waki, Fusako; Matsuishi, Eijo; Kagawa, Kumiko; Furukawa, Tatsuo; Maeda, Yoshinobu; Shimoyama, Manabu; Ago, Hiroatsu; Yamano, Yujiro; Yano, Shingo; Fujishima, Naohito; Takamatsu, Yasushi; Eto, Tetsuya; Hidaka, Michihiro; Matsuoka, Hitoshi; Fukuda, Takahiro.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 12, No. 6, 12.2012, p. 444-451.

Research output: Contribution to journal › Article

Usuki, K, Kurosawa, S, Uchida, N, Yakushiji, K, Waki, F, Matsuishi, E, Kagawa, K, Furukawa, T, Maeda, Y, Shimoyama, M, Ago, H, Yamano, Y, Yano, S, Fujishima, N, Takamatsu, Y, Eto, T, Hidaka, M, Matsuoka, H & Fukuda, T 2012, 'Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission', Clinical Lymphoma, Myeloma and Leukemia, vol. 12, no. 6, pp. 444-451. https://doi.org/10.1016/j.clml.2012.07.004

Usuki, Kensuke ; Kurosawa, Saiko ; Uchida, Naoyuki ; Yakushiji, Kazuaki ; Waki, Fusako ; Matsuishi, Eijo ; Kagawa, Kumiko ; Furukawa, Tatsuo ; Maeda, Yoshinobu ; Shimoyama, Manabu ; Ago, Hiroatsu ; Yamano, Yujiro ; Yano, Shingo ; Fujishima, Naohito ; Takamatsu, Yasushi ; Eto, Tetsuya ; Hidaka, Michihiro ; Matsuoka, Hitoshi ; Fukuda, Takahiro. / Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission. In: Clinical Lymphoma, Myeloma and Leukemia. 2012 ; Vol. 12, No. 6. pp. 444-451.

@article{d3ad1957de4842a98927b601799a08f3,

title = "Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission",

abstract = "Introduction: A number of randomized trials in patients with AML in CR1 have been conducted and they showed that auto-HCT improves RFS but not OS, compared with chemotherapy. However, because these trials have had compliance problems, the value of auto-HCT still has not been clearly established. Patients and Methods: Using a database of 2518 adult patients with AML in CR1, we retrospectively analyzed the outcome of auto-HCT and compared it with intensive nonmyeloablative chemotherapy using landmark analyses. Results: In 103 auto-HCT recipients, OS and RFS at 3 years from treatment were 65% and 57%, respectively. Multivariate analysis showed that unfavorable risk cytogenetics and entry into CR1 after 2 courses of induction treatment predicted a poor outcome. Because the median time interval between CR1 and auto-HCT was 153 days, landmark analyses at 5 months after CR1 were performed to compare 1290 patients who received chemotherapy alone (median age, 52 years; range, 16-70) with 103 who received auto-HCT (median age, 48 years; range, 16-67). Auto-HCT improves 3-year RFS (58% vs. 37%; P ",

keywords = "AML, Autologous transplantation, CR1, inv(16), Postremission therapy, t(8;21)",

author = "Kensuke Usuki and Saiko Kurosawa and Naoyuki Uchida and Kazuaki Yakushiji and Fusako Waki and Eijo Matsuishi and Kumiko Kagawa and Tatsuo Furukawa and Yoshinobu Maeda and Manabu Shimoyama and Hiroatsu Ago and Yujiro Yamano and Shingo Yano and Naohito Fujishima and Yasushi Takamatsu and Tetsuya Eto and Michihiro Hidaka and Hitoshi Matsuoka and Takahiro Fukuda",

year = "2012",

month = dec

doi = "10.1016/j.clml.2012.07.004",

language = "English",

volume = "12",

pages = "444--451",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2669",

publisher = "Cancer Media Group",

number = "6",

}

TY - JOUR

T1 - Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission

AU - Usuki, Kensuke

AU - Kurosawa, Saiko

AU - Uchida, Naoyuki

AU - Yakushiji, Kazuaki

AU - Waki, Fusako

AU - Matsuishi, Eijo

AU - Kagawa, Kumiko

AU - Furukawa, Tatsuo

AU - Maeda, Yoshinobu

AU - Shimoyama, Manabu

AU - Ago, Hiroatsu

AU - Yamano, Yujiro

AU - Yano, Shingo

AU - Fujishima, Naohito

AU - Takamatsu, Yasushi

AU - Eto, Tetsuya

AU - Hidaka, Michihiro

AU - Matsuoka, Hitoshi

AU - Fukuda, Takahiro

PY - 2012/12

Y1 - 2012/12

N2 - Introduction: A number of randomized trials in patients with AML in CR1 have been conducted and they showed that auto-HCT improves RFS but not OS, compared with chemotherapy. However, because these trials have had compliance problems, the value of auto-HCT still has not been clearly established. Patients and Methods: Using a database of 2518 adult patients with AML in CR1, we retrospectively analyzed the outcome of auto-HCT and compared it with intensive nonmyeloablative chemotherapy using landmark analyses. Results: In 103 auto-HCT recipients, OS and RFS at 3 years from treatment were 65% and 57%, respectively. Multivariate analysis showed that unfavorable risk cytogenetics and entry into CR1 after 2 courses of induction treatment predicted a poor outcome. Because the median time interval between CR1 and auto-HCT was 153 days, landmark analyses at 5 months after CR1 were performed to compare 1290 patients who received chemotherapy alone (median age, 52 years; range, 16-70) with 103 who received auto-HCT (median age, 48 years; range, 16-67). Auto-HCT improves 3-year RFS (58% vs. 37%; P

AB - Introduction: A number of randomized trials in patients with AML in CR1 have been conducted and they showed that auto-HCT improves RFS but not OS, compared with chemotherapy. However, because these trials have had compliance problems, the value of auto-HCT still has not been clearly established. Patients and Methods: Using a database of 2518 adult patients with AML in CR1, we retrospectively analyzed the outcome of auto-HCT and compared it with intensive nonmyeloablative chemotherapy using landmark analyses. Results: In 103 auto-HCT recipients, OS and RFS at 3 years from treatment were 65% and 57%, respectively. Multivariate analysis showed that unfavorable risk cytogenetics and entry into CR1 after 2 courses of induction treatment predicted a poor outcome. Because the median time interval between CR1 and auto-HCT was 153 days, landmark analyses at 5 months after CR1 were performed to compare 1290 patients who received chemotherapy alone (median age, 52 years; range, 16-70) with 103 who received auto-HCT (median age, 48 years; range, 16-67). Auto-HCT improves 3-year RFS (58% vs. 37%; P

KW - AML

KW - Autologous transplantation

KW - CR1

KW - inv(16)

KW - Postremission therapy

KW - t(8;21)

UR - http://www.scopus.com/inward/record.url?scp=84869483207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869483207&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2012.07.004

DO - 10.1016/j.clml.2012.07.004

M3 - Article

C2 - 22999942

AN - SCOPUS:84869483207

VL - 12

SP - 444

EP - 451

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 6

ER -

Access to Document

10.1016/j.clml.2012.07.004